Value of clinical indicators in predicting the efficacy of neoadjuvant therapy for esophageal cancer

doi:10.3760/cma.j.cn371439-20250415-00100

Abstract

Abstract:

Neoadjuvant therapy is the preferred treatment mode for locally advanced operable esophageal cancer， and its clinical value has been established through evidence-based medical evidence. Accurately identifying patients who can benefit before or during treatment is of great significance for formulating the overall treatment strategy. Clinical indicators such as age， gender， pathological characteristics， nutritional status， and hematological/histological indicators have certain value in predicting the efficacy of neoadjuvant therapy for esophageal cancer. However， the predictive effect of a single indicator is limited. It is necessary to comprehensively use multiple indicators and combine advanced technologies and methods to provide accurate and practical tools for clinical efficacy prediction.

Key words: Esophageal neoplasms, Neoadjuvant therapy, Response prediction, Clinical indicators

Cheng Honglei, Wang Ti, Lan Zhidong, Gong Heyi. Value of clinical indicators in predicting the efficacy of neoadjuvant therapy for esophageal cancer[J]. Journal of International Oncology, 2025, 52(9): 592-597.

References 36

[1]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[2]	Jeon WJ, Park D, Al-Manaseer F, et al. Survival and treatment patterns in stage Ⅱ to Ⅲ esophageal cancer[J]. JAMA Netw Open, 2024, 7(10): e2440568. DOI: 10.1001/jamanetworkopen.2024.40568.
[3]	van der Zijden CJ, van der Sluis PC, Mostert B, et al. Interval metastases after neoadjuvant chemoradiotherapy for patients with locally advanced esophageal cancer: a multicenter observational cohort study[J]. Ann Surg Oncol, 2024, 31(12): 7759-7766. DOI: 10.1245/s10434-024-15890-w. pmid: 39068317
[4]	Peng K, Xu H, Xie S, et al. Prognostic nomogram for overall survival of elderly esophageal cancer patients receiving neoadjuvant therapy: a population-based analysis[J]. J Gastrointest Oncol, 2024, 15(6): 2376-2388. DOI: 10.21037/jgo-24-392. pmid: 39816016
[5]	Imazeki H, Kato K. Non-cancer-related deaths in patients with resectable locally advanced esophageal squamous cell carcinoma: a supplementary analysis of JCOG 1109[J]. J Clin Oncol, 2025, 53(4): 434. DOI: 10.1200/JCO.2025.43.4_suppl.434.
[6]	Wang J, Ye C, Zhang C, et al. Sex differences in cancer-specific survival for locally advanced esophageal cancer after neoadjuvant chemoradiotherapy: a population-based analysis[J]. Front Surg, 2022, 9: 989204. DOI: 10.3389/fsurg.2022.989204.
[7]	Zhang J, Bellocco R, Ye W, et al. Effect of sex on survival after resection of oesophageal cancer: nationwide cohort study[J]. BJS Open, 2022, 6(3): zrac035. DOI: 10.1093/bjsopen/zrac035.
[8]	Pinton G, Manzotti B, Balzano C, et al. Expression and clinical implications of estrogen receptors in thoracic malignancies: a narrative review[J]. J Thorac Dis, 2021, 13(3): 1851-1863. DOI: 10.21037/jtd-20-2277. pmid: 33841973
[9]	Liu Z, Zhang Y, Lagergren J, et al. Circulating sex hormone levels and risk of gastrointestinal cancer: systematic review and meta-analysis of prospective studies[J]. Cancer Epidemiol Biomarkers Prev, 2023, 32(7): 936-946. DOI: 10.1158/1055-9965.EPI-23-0039.
[10]	Ge F, Huo Z, Cai X, et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis[J]. JAMA Netw Open, 2022, 5(11): e2239778. DOI: 10.1001/jamanetworkopen.2022.39778.
[11]	Al-Kaabi A, van der Post RS, van der Werf LR, et al. Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study[J]. Acta Oncol, 2021, 60(4): 497-504. DOI: 10.1080/0284186X.2020.1870246. pmid: 33491513
[12]	Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2024, 404(10447): 55-66. DOI: 10.1016/S0140-6736(24)00745-1.
[13]	Wang R, Zhou X, Liu T, et al. Gross tumor volume predicts survival and pathological complete response of locally advanced esophageal cancer after neoadjuvant chemoradiotherapy[J]. Front Oncol, 2022, 12: 898383. DOI: 10.3389/fonc.2022.898383.
[14]	Chen D, Mao Y, Zheng Y, et al. Extracapsular lymph node involvement is a robust survival predictor in esophageal cancer patients: a pooled analysis[J]. Eur J Surg Oncol, 2021, 47(8): 1875-1882. DOI: 10.1016/j.ejso.2021.03.247. pmid: 33795171
[15]	Lin CM, Tu CC, Yeh YC, et al. The prognostic impact of extracapsular lymph node involvement in esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2020, 27(8): 3071-3082. DOI: 10.1245/s10434-020-08260-9.
[16]	Yang Y, Liu Z, Sun Y, et al. Clinical characteristics and survival of esophageal cancer patients: annual report of the surgical treatment in Shanghai chest hospital, 2016[J]. J Thorac Dis, 2022, 14(12): 4966-4982. DOI: 10.21037/jtd-22-1672. pmid: 36647485
[17]	Matsuda S, Kawakubo H, Okamura A, et al. Prognostic significance of stratification using pathological stage and response to neoadjuvant chemotherapy for esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2021, 28(13): 8438-8447. DOI: 10.1245/s10434-021-10221-9.
[18]	Matsuda S, Kitagawa Y, Okui J, et al. Nationwide validation study of the prognostic significance of stratification using pathological stage and response to neoadjuvant chemotherapy for esophageal squamous cell carcinoma[J]. Ann Surg, 2023, 278(2): e234-e239. DOI: 10.1097/SLA.0000000000005701.
[19]	Hagi T, Makino T, Yamasaki M, et al. Pathological regression of lymph nodes better predicts long-term survival in esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery[J]. Ann Surg, 2022, 275(6): 1121-1129. DOI: 10.1097/SLA.0000000000004238.
[20]	Yuan Y, Ma G, Hu X, et al. Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: a SEER study[J]. Cancer Med, 2020, 9(13): 4648-4655. DOI: 10.1002/cam4.2997.
[21]	Song N, Wang Z, Sun Q, et al. Efficacy, safety, and prognostic modeling in neoadjuvant immunotherapy for esophageal squamous cell carcinoma[J]. Int Immunopharmacol, 2024, 142(Pt A): 112845. DOI: 10.1016/j.intimp.2024.112845.
[22]	Kang J, Lee HP, Kim HR, et al. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma[J]. Surg Oncol, 2020, 35: 491-497. DOI: 10.1016/j.suronc.2020.10.015. pmid: 33130441
[23]	Bullock AF, Greenley SL, McKenzie GAG, et al. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis[J]. Eur J Clin Nutr, 2020, 74(11): 1519-1535. DOI: 10.1038/s41430-020-0629-0.
[24]	Wang P, Wang S, Li X, et al. Skeletal muscle wasting during neoadjuvant therapy as a prognosticator in patients with esophageal and esophagogastric junction cancer: a systematic review and meta-analysis[J]. Int J Surg, 2022, 97: 106206. DOI: 10.1016/j.ijsu.2021.106206.
[25]	Jin SB, Tian ZB, Ding XL, et al. The impact of preoperative sarcopenia on survival prognosis in patients receiving neoadjuvant therapy for esophageal cancer: a systematic review and meta-analysis[J]. Front Oncol, 2021, 11: 619592. DOI: 10.3389/fonc.2021.619592.
[26]	Harada T, Tsuji T, Ueno J, et al. Clinical mechanism of muscle mass loss during neoadjuvant chemotherapy in older patients with esophageal cancer: a prospective cohort study[J]. Dis Esophagus, 2025, 38(1): doae096. DOI: 10.1093/dote/doae096.
[27]	Harada T, Tsuji T, Ueno J, et al. Prognostic impact of the loss of skeletal muscle mass during neoadjuvant chemotherapy on older patients with esophageal cancer[J]. Ann Surg Oncol, 2022, 29(13): 8131-8139. DOI: 10.1245/s10434-022-12379-2.
[28]	Yoon HG, Oh D, Noh JM, et al. Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer[J]. J Cachexia Sarcopenia Muscle, 2021, 12(5): 1144-1152. DOI: 10.1002/jcsm.12747. pmid: 34145771
[29]	Li B, Xiong F, Yi S, et al. Prognostic and clinicopathologic signi-ficance of neutrophil-to-lymphocyte ratio in esophageal cancer: an update meta-analysis[J]. Technol Cancer Res Treat, 2022, 21: 15330338211070140. DOI: 10.1177/15330338211070140.
[30]	Zhao K, Wang C, Shi F, et al. Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma[J]. Transl Cancer Res, 2020, 9(6): 3842-3853. DOI: 10.21037/tcr-19-2849. pmid: 35117751
[31]	Xu J, Hong Z, Cai Y, et al. Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China[J]. Front Oncol, 2024, 14: 1279733. DOI: 10.3389/fonc.2024.1279733.
[32]	Wu P, Zhang Z, Yuan Y, et al. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: a multicenter study in China[J]. Int J Surg, 2022, 107: 106960. DOI: 10.1016/j.ijsu.2022.106960.
[33]	Yehan Z, Sheng Q, Hong Y, et al. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment[J]. Front Immunol, 2024, 15: 1312380. DOI: 10.3389/fimmu.2024.1312380.
[34]	de Klerk LK, Goedegebuure RSA, et al. Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies[J]. Mol Oncol, 2021, 15(4): 901-914. DOI: 10.1002/1878-0261.12907. pmid: 33506581
[35]	Liu G, Chen T, Zhang X, et al. Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma[J]. Cancer Med, 2024, 13(5): 7075. DOI: 10.1002/cam4.7075.
[36]	Qi Y, Hu Y, Lin C, et al. A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients[J]. Front Immunol, 2025, 16: 1530279. DOI: 10.3389/fimmu.2025.1530279.